APA

Iannantuoni F., M de Marañon A., Diaz-Morales N., Falcon R., Bañuls C., Abad-Jimenez Z., Victor V. M., Hernandez-Mijares A. & Rovira-Llopis S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. : Journal of clinical medicine.

Chicago

Iannantuoni Francesca, M de Marañon Aranzazu, Diaz-Morales Noelia, Falcon Rosa, Bañuls Celia, Abad-Jimenez Zaida, Victor Victor M, Hernandez-Mijares Antonio and Rovira-Llopis Susana. 2019. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. : Journal of clinical medicine.

Harvard

Iannantuoni F., M de Marañon A., Diaz-Morales N., Falcon R., Bañuls C., Abad-Jimenez Z., Victor V. M., Hernandez-Mijares A. and Rovira-Llopis S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. : Journal of clinical medicine.

MLA

Iannantuoni Francesca, M de Marañon Aranzazu, Diaz-Morales Noelia, Falcon Rosa, Bañuls Celia, Abad-Jimenez Zaida, Victor Victor M, Hernandez-Mijares Antonio and Rovira-Llopis Susana. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. : Journal of clinical medicine. 2019.